Oncology Signaling

Open access

ISSN: 2542-5633

Oncology Signaling

Open access

Cancer signaling has become fundamental in our understanding and treatment of cancer. It will become essential in the development of precision medicine for cancer. Oncology Signaling welcomes the subm...

Cancer signaling has become fundamental in our understanding and treatment of cancer. It will become essential in the development of precision medicine for cancer. Oncology Signaling welcomes the submission of research papers which investigates all aspects of signal transduction in oncology. This includes both basic science discovery and translational research.

Manuscripts detailing fundamental research on all aspects of oncology signaling will be considered. Papers describing the mechanisms of action of signaling pathways in cancer and how this relates to current treatments for cancer will be a focus. Potential research article topics include, but are not limited to:

  • Role of protein kinases
  • Lipid signaling
  • NO signaling and ion channels
  • Regulation of secondary messengers
  • Receptor functions
  • Guanine nucleotide regulatory proteins
  • Bioinformatic studies relevant to cell signaling
  • Micro-environmental signals
  • Anchor-scaffold signaling proteins
  • Targeted therapies
  • Chemotherapeutic drug mechanisms of action
  • Effects of signaling on the growth and differentiation of cancer cells

Authors should address the question of how their research results compare with previously reported studies. This could be in original research study or a relevant review of current advances in the oncology signaling. Short communications or research letters would also be acceptable. Manuscripts with emerging themes and ideas in oncology signaling will be encouraged to submit to this journal. The manuscripts should contain proper statistical treatment of the data. Relevant literature should be cited, including related publications by the authors.

Targeting cGMP/PKG signaling for the treatment or prevention of colorectal cancer with novel sulindac derivatives lacking cyclooxygenase inhibitory activity

Inhibition of dipeptidyl peptidase 4 (DPP4) activates immune cells chemotaxis in hepatocellular carcinoma

Adequacy of sonographic guided fine needle aspiration cytology (FNAC) in abdominal lesions highlighting on malignant pathologies – A 10 year experience

View all ScienceDirect

1. Inhibition of dipeptidyl peptidase 4 (DPP4) activates immune cells chemotaxis in hepatocellular carcinoma

2. Targeting cGMP/PKG signaling for the treatment or prevention of colorectal cancer with novel sulindac derivatives lacking cyclooxygenase inhibitory activity

3. Adequacy of sonographic guided fine needle aspiration cytology (FNAC) in abdominal lesions highlighting on malignant pathologies – A 10 year experience

View all ScienceDirect

Call for Papers

Cancer Pharmacology and Precision Cancer Therapy

View all

Stay informed

Register your interest and receive email alerts tailored to your needs. Sign up below.